Anhydrates and Hydrates of Olanzapine: Crystallization, Solid-State Characterization, and Structural Relationships

Crystal Growth and Design

Volumn 3, Issue 6, 2003, Pages 897-907

  Reutzel Edens, Susan M ^a   Bush, Julie K ^a   Magee, Paula A ^a   Stephenson, Greg A ^a   Byrn, Stephen R ^b  

^a ELI LILLY AND COMPANY   (United States)

^b PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OLANZAPINE;

ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CONFORMATION; CRYSTAL STRUCTURE; CRYSTALLIZATION; CRYSTALLOGRAPHY; HYDROGEN BOND; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PSYCHOSIS; SCHIZOPHRENIA; SOLID; THERMODYNAMICS; X RAY CRYSTALLOGRAPHY;

EID: 0344583871     PISSN: 15287483     EISSN: None     Source Type: Journal    
DOI: 10.1021/cg034055z     Document Type: Article

References (57)

1. Desiraju, G. R. Crystal Engineering: The Design of Organic Solids; Elsevier: New York, 1989.
2. Hollingsworth, M. D. Science 2002, 295, 2410-2413.
3. Fan E.; Vicent, C.; Geib, S. J.; Hamilton, A. D. Chem. Mater. 1994, 6, 1113-1117.
4. Nangia, A.; Desiraju, G. R. Acta Crystallogr. 1998, A54, 934.
5. Aakeröy, C. B. Acta Cryst. 1997, B53, 569-586.
6. Byrn, S. R. Solid State Chemistry of Drugs; Academic Press: New York, 1982.
7. Fleisher, D.; Bong, R.; Stewart, B. H. Adv. Drug. Del. Rev. 1996, 19, 115.
8. Pop, E. Curr. Med. Chem. 1997, 4, 279.
9. Berge, S. M.; Bighley, L. D.; Monkhouse, D. M. J. Pharm. Sci. 1977, 66, 1.
10. Gould, P. L. Int. J. Pharm. 1986, 33, 201.
11. Bastin, R. J.; Bowker, M. J.; Slater, B. J. Org. Process Res. Dev. 2000, 4, 427-435.
12. Hirayama, F.; Uekama, K. Cyclodextrins and their Industrial Uses; Editions de Santé: Paris, 1987.
13. Rajewski, R. A.; Stella, V. J. J. Pharm. Sci. 1996, 85, 1142-1169.
14. Loftsson, T.; Brewster, M. E. J. Pharm. Sci. 1996, 85, 1017-1025.
15. Venkatramana, M. R.; Stella, V. J. J. Pharm. Sci. 2003, 92(5), 927-932.
16. Kalinkova, G. N. Int. J. Pharm. 1999, 187, 1-15, and references therein.
17. Pedersen, S.; Kristensen, H. G.; Cornett, C. S. T. P. Pharma Sci. 1994, 4, 292.
18. Bettinetti, G. P.; Caria, M. R.; Callegari, A.; Merli, M.; Sorrenti, M.; Tadini, C. J. Pharm. Sci. 2000, 891, 478-489.
19. Morris, K. R. Drugs Pharmaceutical Science: 95. Polymorphism in Pharmaceutical Solids; Marcel Dekker: New York, 1999.
20. Halebian, J.; McCrone, W. J. Pharm. Sci. 1969, 58, 911-929.
21. Bernstein, J. Polymorphism in Molecular Crystals; Clarendon: Oxford, 2002.
22. Bernstein J.; Henck, J.-O. Cryst. Eng. 1998, 1, 119-128.
23. Caira, M. R. Top. Curr. Chem. 1998, 198, 163-208.
24. Bernstein, J. J. Phys. D: Appl. Phys. 1993, 26, B66-76.
25. Fulton, B.; Goa, K. L. Drugs 1997, 53(2), 281-298.
26. Tollefson, G. D.; Beasley, C. M., Jr.; Tran, P. V.; Street, J. S.; Krueger, J. A.; Tamura, R. N.; Graffeo, K. A.; Thieme, M. E. Am. J. Psychiatry 1997, 154(4), 457-465.
27. Cambridge Structural Database, Version 5.24; Cambridge Crystallographic Data Centre: Cambridge, UK, November 2002 update.
28. Sheldrick, G. M. SHELX86: Program for the Solution of Crystal Structures; University of Gottingen, Germany, 1986.
29. Fair, C. K. MolEN Structure Determination System; Delft Instruments: Delft, The Netherlands, 1990.
30. Killean, R. C. G.; Lawrence, J. L. Acta Cryst. 1969, B25, 1750.
31. International Tables for X-ray Crystallography, Vol. IV; Kynoch Press: Birmingham, England, 1974; Table 2.2B.
32. Ibers, J. A.; Hamilton, W. C. Acta Cryst. 1964, 17, 781.
33. Molecular Simulations, Inc. Cerius2 Molecular Modeling Program, Version 3.9; Molecular Simulations: San Diego, 1998.
34. SMART, Version 5.05; Bruker AXS, Inc.: Madison, Wisconsin, 1998.
35. SAINT, Version 6.2, Bruker AXS, Inc.: Madison, Wisconsin, 2001.
36. Sheldrick, G. M. SHELXTL V5.1; Madison, WI, 1998.
37. The crystal structure of the EtOH-water solvate will be disclosed in a separate report.
38. Rietveld, H. M. Aust. J. Phys. 1988, 41, 113.
39. Wiles, P. E.; Young, R. A. J. Appl. Cryst. 1981, 14, 149.
40. Spartan, Version 5.0; Wavefunction, Inc.: Irvine, CA, 1992.
41. Rapid interconversion of diazepine ring conformers has also been observed in the structurally related dibenzodiazepine, clozapine and is attributed to the low activation energy for inversion. Petcher, T. J.; Weber, H.-P. J. Chem. Soc., Perkin Trans. 2 1976, 1415-1420.
42. 2 hemisolvate), for which X-ray structures have been determined, each feature the olanzapine dimer.
43. Refcodes for retrieved structures: CIJMIR, HIFRET, NDNCLH01, NDNHCL01, NDNHCL10, and YUYMUA.
44. The energetically equivalent mirror image of conformer A was also obtained.
45. Analysis of hydrogen-bonding patterns in small peptides has previously revealed that water most frequently donates two hydrogen bonds and accepts one. The criteria for hydrogen bonding outlined by Görbitz and Etter were used to establish the hydrogen-bonding topology in the olanzapine dihydrates. Görbitz, C. H.; Etter, M. C. Int. J. Peptide Protein Res. 1992, 39, 93-110.
46. Because the water hydrogens were not located in the crystal structure determinations, nonbonded contacts to the waters of crystallization were identified by carefully examining heavy atom distances, with consideration given to hydrogen-bond angles.
47. Harris R. K.; Olivieri, A. C. Prog. NMR Spectrosc. 1992, 24, 435-456.
48. Levy, G. C.; Lichter, R. L. Nitrogen-15 Nuclear Magnetic Resonance Spectroscopy; John Wiley & Sons, New York, 1979.
49. 15N resonance will shift to higher or lower frequencies, respectively. Naito, A.; Tuzi, S.; Saito, H. Eur. J. Biochem. 1994, 224, 729-734.
50. Taylor, R.; Kennard, O. J. Am. Chem. Soc. 1982, 104, 5063-5070.
51. Byrn, S.; Pfeiffer, R.; Ganey, M.; Hoiberg, C.; Poochikian, G. Pharm. Res. 1995, 12, 945-954.
52. Ostwald, W. F. Z. Phys. Chem. (Leipzig) 1897, 22, 289-330.
53. 3, respectively, were calculated.
54. McCrone, W. C. Physics and Chemistry of the Organic Solid State; Interscience: New York, 1963.
55. Lommerse, J. P. M.; Motherwell, W. D. S.; Amon, H. L.; Dunitz, J. D.; Gavezzotti, A.; Hofmann, D. W. M.; Leusen, F. J. J.; Mooij, W. T. M.; Price, S. L.; Schweizer, B.; Schmidt, M. U.; van Eijck, B. P.; Verwer, P.; Williams, D. E. Acta Cryst. 2000, B56, 697-714.
56. There are numerous examples of highly studied pharmaceutical compounds (aspirin (ACSALA01), ibuprofen (IBPRAC), and fluoxetine HCl (FUDCOW) - the active ingredient in Prozac, to name a few) that, to date, are monomorphic.
57. Blagden N. Powder Tech. 2001, 121, 46-52.